Sign up Australia
Proactive Investors - Run By Investors For Investors

Ellex Medical Lasers treatment receives German praise

Ellex Medical Lasers treatment receives German praise

Ellex Medical Lasers’ (ASX:ELX) proprietary Canaloplasty technology has been recognised as the new ‘gold standard’ in the surgical treatment of glaucoma by patient advocacy group The German Federate Eye Association.

This is a step towards the technology being recognised as the standard of care for glaucoma surgery worldwide.

The glaucoma surgical device market is valued at about A$275 million. This is expected to grow at an annual rate of 24% to reach $A$870 million by 2019.


Canaloplasty

Canaloplasty uses the company’s patented iTrack microcatheter to enlarge the eye’s natural drainage system.

Unlike traditional trabeculectomy surgery, which creates an artificial drainage channel, Canaloplasty restores the function of the eye’s natural outflow system in order to reduce the elevated intraocular pressure associated with glaucoma.

Being minimally invastive, Canaloplasty provides an improved safety profile and allows surgeons to reduce or eliminate many post-operative complications.



Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

View full ELX profile View Profile

Ellex Medical Lasers Timeline

Newswire
November 30 2016

Related Articles

1528305384_Untitled-design-(3).jpg
June 07 2018
Ventripoint received key FDA approval to sell the device with the four-chamber heart analysis last month
picture of addict
November 16 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix
1511901712_biotech_517925923.jpg
November 29 2017
The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use